See today's BioWorld Science
To read the full story, subscribe or sign in.
Ocular

Ascidian’s RNA exon editor cleared to enter clinic for Stargardt disease

Jan. 30, 2024
Ascidian Therapeutics Inc. has received FDA clearance of its IND application for ACDN-01, an RNA exon editor targeting the genetic cause of Stargardt disease.
BioWorld Science Regulatory Ocular FDA IND